Sales & Marketing At BIO 2024, an industry vows to reclaim its narrative At BIO2024 experts agreed that in a period where pharma is deeply unpopular, the industry must be proactive in telling its story.
R&D Headlines and hot topics from ASCO and BIO, with Jonah Comst... This week, pharmaphorum editor-in-chief Jonah Comstock headed to not one, but two back-to-back events in the US.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.